Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial

Louise Bouard (1) , Catherine Thieblemont (2) , Krimo Bouabdallah (3) , Thomas Gastinne (4) , Anne Moreau (4, 5) , Sibylle Masse , Remy Gressin (6) , Lucie Oberic (7) , Alexis Caulier (8, 9) , Emmanuel Gyan (10, 11) , Victoria Cacheux (12) , Olivier Casasnovas (13) , Olivier Hermine (14) , Steven Le Gouill (4)

1 Département d'Hématologie [CHU Nantes]
2 AP-HP - Hopital Saint-Louis [AP-HP]
3 CHU Bordeaux [Bordeaux]
4 CHU Nantes - Centre hospitalier universitaire de Nantes
5 CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
6 CHU - Centre Hospitalier Universitaire [Grenoble]
7 Service Hématologie - IUCT-Oncopole [CHU Toulouse]
8 CHU Amiens-Picardie
9 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
10 CHU Trousseau [Tours]
11 TSE-R - Toulouse School of Economics
12 CHU Clermont-Ferrand
13 CHU Dijon
14 ERL 8254 - Mécanismes cellulaires et moléculaires des désordres hématologiques et implications thérapeutiques = Molecular mechanisms of hematological disorders and therapeutic implications

Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial

Domaines: Sciences du Vivant [q-bio]

Louise Bouard, Catherine Thieblemont, Krimo Bouabdallah, Thomas Gastinne, Anne Moreau, et al.. Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial. Blood, 2020, 136 (1), pp.42. ⟨10.1182/blood-2020-139990⟩. ⟨hal-03605964⟩